James D. Carroll

37 years photobiomodulation (PBM) experience (designing, manufacturing, educating, inspiring). Founded the industry-leading PBM company THOR Photomedicine. Collaborates with the foremost Photobiomodulation (PBM) academics in over 50 academic institutions, authored/co-authored 68 PBM papers and contributed chapters to five PBM books. Recognised authority on PBM dose, dose-rate effects, and the measurement and reporting of parameters. Widely Known as "the world's leading ambassador for Photobiomodulation".

THOR’s equipment has delivered more than 36 million treatments.
Customers include: St Jude, Harvard School of Public-Health, MGH, MIT, Brigham and Women’s Hospital, VA hospitals, US Special Forces, NFL, NBA, MLB, NHL, UFC, Olympic teams, tech billionaires and Hollywood celebrities.

Co-Founder and Investor in Lumithera Inc, developing PBM technologies for the leading cause of blindness in the developed world (Dry age-related macular degeneration) and other ocular diseases.

Appointments
Co-chairs the annual Biomedical Optics Society conference on PBM Mechanisms (2009–present)
Fellow of The Royal Society of Medicine (2009–present)
Editorial Board of Photobiomodulation and Laser Surgery (2008–2013)
Board Member World Association for PBM (2000–2004 and 2018–present)
Board Member North American Association for Laser Therapy (2002–2006)

Notable Speaking Events
Congressional briefing on PBM as a solution for the opioid crisis
White House briefing on PBM as a solution for the opioid crisis
United Nations Global Health Impact Forum presentation on PBM treatment of dry AMD

AWARDS
2020 - World Association for Photobiomodulation Therapy, Presidential Commendation for service and leadership in the field of Photobiomodulation
2021 - T.H. Maiman Award for excellence in medical laser research